Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients
Related Experiment Video
Updated: Jan 31, 2026

Flow Cytometric Analysis of Apoptotic Biomarkers in Actinomycin D-Treated SiHa Cervical Cancer Cells
Published on: August 26, 2021
M A Karsdal1, K M Verburg2, C R West2
1Nordic Bioscience, Herlev Hovedgade, DK-2730 Herlev, Denmark.
Abstract:
There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of patients.
Aim:
The aim of this study was to phenotype with biochemical biomarkers of bone, cartilage, soft tissue, synovial metabolism OA patients who are at risk of developing RPOA type-2, for both limited and chronic NSAIDs users.
Material And Methods:
The dataset consisted of OA patients participating in tanezumab trials who used NSAIDs <90 days (limited NSAID users) or chronic users (NSAIDs ≥90 days) over an average 10 month period. Biomarker data were available for 47 cases (RPOA type-2) and 92 controls. Non-linear and linear multivariable predictive models were developed.
Results:
By use of two biomarkers at baseline the receiver operating characteristic (ROC) curve area for RPOA type-2 in limited NSAID users was 71%, [CI] (60-83%). OA subjects with this biomarker phenotype had 8-fold higher confidence interval [CI][(2-33)] relative risk of developing RPOA type-2 as compared to OA patients without this phenotype. The AUC of the model in chronic NSAIDs users based on 5 biomarkers was 78%, [CI](69-88%), with 4-fold [CI (2-6)] relative risk of developing RPOA type-2.
Conclusion:
In this hypothesis generating and exploratory study, we identified combinations of biomarkers associated with OA patients who develop RPOA type-2, which may be related to the pathology of the RPOA type-2 joint.
Insights
Biomarkers can predict rapidly progressive osteoarthritis (RPOA) in osteoarthritis (OA) patients treated with tanezumab. This study identified specific biomarker combinations to identify patients at risk of RPOA type-2.
Area of Science:
- Biochemistry
- Orthopedics
- Pharmacology
Background:
- Osteoarthritis (OA) requires effective and safe pain management.
- Tanezumab, a nerve growth factor (NGF) antibody, shows high efficacy but carries a risk of rapidly progressive osteoarthritis (RPOA) when combined with chronic NSAID use.
- Identifying OA patients at risk for RPOA is crucial for safe treatment.
Purpose of the Study:
- To identify biochemical biomarkers predicting RPOA type-2 in OA patients.
- To phenotype OA patients at risk for RPOA type-2, considering both limited and chronic NSAID users.
- To develop predictive models for RPOA type-2 risk.
Main Methods:
- Analyzed biomarker data from OA patients in tanezumab trials, categorized by NSAID usage (limited <90 days, chronic ≥90 days).
- Utilized 47 RPOA type-2 cases and 92 controls.
- Developed non-linear and linear multivariable predictive models.
Main Results:
- In limited NSAID users, two baseline biomarkers predicted RPOA type-2 with 71% ROC AUC, showing an 8-fold increased relative risk.
- In chronic NSAID users, five biomarkers predicted RPOA type-2 with 78% AUC, indicating a 4-fold increased relative risk.
- Identified specific biomarker combinations associated with RPOA type-2 development.
Conclusions:
- Biomarker combinations can identify OA patients at risk for RPOA type-2.
- These findings may elucidate the underlying pathology of RPOA type-2.
- This exploratory study provides a basis for future research into RPOA prevention and management.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Taping Over Different Ground Profiles
Rapidly Varying Flow

